Skip to main content
. 2021 Dec 2;32(4):2178–2187. doi: 10.1007/s00330-021-08364-0

Table 1.

Baseline characteristics of study participants

Patients with available index CTPAs (n = 341)
Age (mean ± SD) 56 (16)
Male sex (n, %) 167 (49)
BMI (mean ± SD) 28 (5.9)
Unprovoked PE (n, %) 188 (55)
High-risk PE* (n, %) 9 (2.6)
A prior history of VTE (n, %) 71 (21)
Onset of symptoms > 2 weeks before index PE diagnosis (n, %) 73 (21)
Comorbidities (n, %)
Anaemia 71 (21)
COPD/asthma 38 (11)
Active malignancy# 31 (9.1)
Diabetes mellitus 24 (7.0)
Coronary artery disease 22 (6.5)
Rheumatic disease^ 15 (4.4)
Hypothyroidism 14 (4.1)
Known antiphospholipid antibodies 5 (1.5)
Interstitial lung disease 4 (1.2)
Inflammatory bowel disease 4 (1.2)
Major vasculitis syndromes 2 (0.6)
Prior infected pacemaker leads 1 (0.3)
Splenectomy 1 (0.3)
Anticoagulant treatment at 3-month follow-up visit
DOAC 233 (68)
VKA 87 (26)
LMWH 29 (8.5)

Note:

*According to the 2019 European Society of Cardiology Guidelines on Acute PE

#Active malignancy was defined as follows: diagnosis of cancer within 6 months prior to enrolment, any treatment for cancer within the previous 6 months or recurrent metastatic cancer

^Rheumatic disease was defined as follows: known rheumatic arthritis, osteoarthritis, connective tissue disease, systemic lupus erythematosus, ankylosing spondylitis or Sjögren syndrome

Abbreviations: PE, pulmonary embolism; SD, standard deviation; BMI, body mass index; VTE, venous thromboembolism; COPD, chronic obstructive pulmonary disease; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonist; DOAC, direct oral anticoagulant. Anaemia was defined as: males < 8.5 mmol/L or < 13.5 g/dL; females < 7.5 mmol/L or < 12.0 g/dL